Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.prro.2021.05.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ASTRO Guidelines for Partial Breast Irradiation for Patients With Early-Stage Invasive Breast Cancer: A Disturbing Change of Paradigm for Intraoperative Radiation Therapy. Editorial on Behalf of the International Society of Intraoperative Radiation Therapy Working Group.
Pract Radiat Oncol
January 2025
Department of Radiation-Oncology, Institut Jules Bordet - Université Libre de Bruxelles, Brussels, Belgium. Electronic address:
Time to Slash SABR From Our Lexicon.
Pract Radiat Oncol
November 2024
David Geffen School of Medicine at UCLA, Los Angeles, California.
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929.
J Thorac Oncol
November 2024
UC Davis Comprehensive Cancer Center, Sacramento, California.
Article Synopsis
- The study aimed to assess if adding the PARP inhibitor talazoparib to the immune checkpoint inhibitor atezolizumab could enhance outcomes for patients with SLFN11-positive extensive stage small cell lung cancer (ES-SCLC) after initial treatment.
- A total of 106 patients were randomized into two groups, showing that the combination therapy (talazoparib plus atezolizumab) led to improved progression-free survival compared to atezolizumab alone, though overall survival rates remained similar between the two groups.
- While the combination therapy improved progression-free survival, it also resulted in higher rates of severe hematological side effects, such as grade 3 anemia, highlighting the need for careful patient selection based on genetic markers
ASTRO's Advances in Radiation Oncology's Top Downloaded Articles of 2023.
Adv Radiat Oncol
August 2024
Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts.
Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC.
J Thorac Oncol
January 2025
Yale University School of Medicine, New Haven, Connecticut.
Introduction: Patients with advanced ALK-positive NSCLC typically have poor response to immunotherapy; the benefit of consolidation durvalumab in patients with unresectable stage III ALK-positive NSCLC remains unclear. Herein, we compare the efficacy and safety of consolidation ALK tyrosine kinase inhibitor (TKI) versus durvalumab or observation after concurrent chemoradiation.
Methods: We conducted a retrospective study using a multicenter study of 17 institutions globally.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!